Drug Profile
Research programme: antiparkinsonian therapies - PixarBio Corporation
Alternative Names: Dopamine - PixarBio Corporation; Dopamine agonists - PixarBio CorporationLatest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator PixarBio Corporation
- Class Antiparkinsonians; Cardiotonics; Catecholamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Parkinson's-disease in USA (Parenteral, Injection)
- 19 Mar 2018 Development is ongoing for Parkinson’s disease in USA (PixarBio Corporation website, March 2018)